home / stock / mynz / mynz quote
Last: | $0.74 |
---|---|
Change Percent: | -0.45% |
Open: | $0.74 |
Close: | $0.74 |
High: | $0.795 |
Low: | $0.74 |
Volume: | 63,109 |
Last Trade Date Time: | 05/06/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.74 | $0.74 | $0.74 | $0.795 | $0.74 | 63,109 | 05-06-2024 |
$0.7367 | $0.7909 | $0.7367 | $0.795 | $0.72 | 169,564 | 05-03-2024 |
$0.765101 | $0.785 | $0.765101 | $0.815 | $0.751 | 194,251 | 05-02-2024 |
$0.75 | $0.88 | $0.75 | $0.88 | $0.7352 | 138,896 | 05-01-2024 |
$0.8799 | $0.879 | $0.8799 | $0.9 | $0.867 | 45,126 | 04-30-2024 |
$0.867 | $0.8179 | $0.867 | $0.9105 | $0.79 | 347,543 | 04-29-2024 |
$0.8181 | $0.85 | $0.8181 | $0.8794 | $0.78 | 309,587 | 04-26-2024 |
$0.8568 | $1 | $0.8568 | $1.08 | $0.81 | 1,085,328 | 04-25-2024 |
$0.8987 | $0.888 | $0.8987 | $0.9 | $0.8578 | 64,814 | 04-24-2024 |
$0.869 | $0.8999 | $0.869 | $0.9278 | $0.85 | 75,878 | 04-23-2024 |
$0.8705 | $0.9 | $0.8705 | $0.94 | $0.86 | 66,374 | 04-22-2024 |
$0.905 | $0.89 | $0.905 | $0.95 | $0.88 | 62,539 | 04-19-2024 |
$0.904 | $0.92 | $0.904 | $0.94 | $0.9 | 52,049 | 04-18-2024 |
$0.9312 | $0.9 | $0.9312 | $0.975 | $0.9 | 22,575 | 04-17-2024 |
$0.9534 | $0.95 | $0.9534 | $0.98 | $0.92 | 25,860 | 04-16-2024 |
$0.98 | $1 | $0.98 | $1 | $0.95 | 57,633 | 04-15-2024 |
$0.97 | $1 | $0.97 | $1.04 | $0.97 | 77,933 | 04-12-2024 |
$1.005 | $1.03 | $1.005 | $1.04 | $0.99505 | 66,740 | 04-11-2024 |
$1.05 | $1.04 | $1.05 | $1.08 | $0.9911 | 89,478 | 04-10-2024 |
$0.99 | $1.09 | $0.99 | $1.13 | $0.99 | 103,756 | 04-09-2024 |
News, Short Squeeze, Breakout and More Instantly...
Mainz Biomed B.V. Company Name:
MYNZ Stock Symbol:
NASDAQ Market:
BERKELEY, Calif. and MAINZ, Germany, May 07, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, will present an analysis from its eAArly DETECT study at Digestive Disease Week (DDW) 2024 in Washington D....
Groundbreaking topline results demonstrated sensitivity for colorectal cancer of 92% with specificity of 90% and best-in-class sensitivity for advanced adenoma of 82% 690 subjects analyzed including previously unexamined and reported patients from Company’s ColoFuture and eAArl...
Bristol Myers Squibb (NYSE: BMY), Merck & Co Inc (NYSE: MRK), Pfizer Inc (NYSE: PFE) and Johnson & Johnson(NYSE: JNJ) a...